AI
CHRS icon

Atria Investments’s Coherus Oncology CHRS Stock Holding History

Atria Investments’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$63.2K Buy
+37,391
New +$66.4K ﹤0.01% 2021

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Atria Investments's CHRS Position: Q1 2026 in Review

Atria Investments opened a new position in Coherus Oncology (CHRS) in Q1 2026: 37,391 shares worth $63.2K. The stake represents ﹤0.01% of the portfolio and ranks #2021 among its holdings.

157 funds tracked by Wall St. Rank hold CHRS as of Q1 2026.

  • Atria Investments held 37,391 shares of Coherus Oncology worth $63.2K as of Q1 2026.
  • Coherus Oncology was a new Atria Investments position in Q1 2026.
  • Coherus Oncology made up ﹤0.01% of Atria Investments's portfolio in Q1 2026, its #2021 holding.
  • 157 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2026.

Based on Atria Investments's 13F filing for Q1 2026, filed 5 May 2026.